Pink Sheet Podcast: CMS Listens On Price Negotiations, Elevidys Top-Line Trial Data, Gene Therapy Reg Changes
Pink Sheet reporters and editor discuss take-aways from the first Medicare price negotiation program public listening sessions, next steps after Sarepta reported questionable top-line data for its Duchenne muscular dystrophy gene therapy Elevidys, and indications the FDA may adjust its regulatory approach to gene editing products.
You may also be interested in...
Infographic: One of the more prominent arguments against the Medicare drug price negotiation program is that by limiting the number of years that products can be marketed before price caps are imposed, the scheme discourages development of additional indications.
Legislation to delink PBM payments from drug prices advances in House Energy and Commerce health subcommittee, putting a key pharma priority closer to the finish line. Whether patients will see any benefit remains a worry.
While many interpretations of the law protecting the first interchangeable biosimilar approved for a reference product are included in a recently released FDA memo, the agency says it has a limited scope.